Results 71 to 80 of about 8,506 (160)

[Safety in the selection of oral antibiotic treatment in community infections, beyond COVID-19]. [PDF]

Rev Esp Quimioter, 2021
Barberán J, Barberán LC, de la Cuerda A.   +2 more
europepmc   +1 more source

[Adverse reactions of drugs specifically used for treatment of SARS-CoV-2 infection]. [PDF]

Med Clin (Barc), 2020
Herrera-Lasso Regás V, Dordal Culla MT, Lleonart Bellfill R.   +2 more
europepmc   +1 more source

[Systemic and extrapulmonary manifestations of COVID-19]. [PDF]

Medicine (Baltimore), 2022
Vázquez JB, Menchén DA, Lloréns MMM, Moreno JS.   +3 more
europepmc   +1 more source

[Fibromyalgia in the new era of SARS-CoV-2 infection and post-COVID-19 syndrome: A scoping review]. [PDF]

Rev Colomb Reumatol, 2022
Tuta-Quintero E, Mora-Karam C, Pimentel J.   +2 more
europepmc   +1 more source

Study of the indications for macrolide prescriptions in a Colombian population [PDF]

Biomedica, 2022
Valladales-Restrepo LF, Constain-Mosquera CA, Hoyos-Guapacha MA, Hoyos-Guapacha KL, Gaviria-Mendoza A, Machado-Duque ME, Machado-Alba JE.   +6 more
europepmc   +1 more source

[Drug Excipients. Necessary, but not Harmless]. [PDF]

Farm Comunitarios
López Alarcón MD, Justo Hernández A, Santos Cruz P.   +2 more
europepmc   +1 more source

Estado actual de los tratamientos para la COVID-19. [PDF]

FMC, 2021
Llover MN, Jiménez MC.
europepmc   +1 more source

Sindrome del hombre rojo en niños de 0-14 de edad por el uso de vancomicina en el Hospital MAterno Infantil Fernando Vélez Paiz,Managua, Enero 2008-Julio 2009 [PDF]

, 2010
Galeano Chacon, Linley Berenice, Gonzalez Calderon, Cherie Sugey   +1 more
core  

Medicines withdrawn in other countries due to safety problems, between 2014 and 2023, and their permanence in the Argentine market. [PDF]

Rev Fac Cien Med Univ Nac Cordoba
Caffaratti M, Cañás M, Domosbian DE, Giraudo E, González AM, Lorenzo A, Núñez Montoya S, Rocha MT, Traverso ML, Uema S.   +9 more
europepmc   +1 more source